Literature DB >> 26154692

Effects of Isotretinoin on Meibomian Glands.

Allison Moy1, Nancy A McNamara, Meng C Lin.   

Abstract

The authors have reviewed the potential etiology and long-standing consequences of isotretinoin use in the development of dry eye symptoms in the absence of significant clinical findings. Despite the normal appearance of meibomian gland structure on meibography and minimal signs of eyelid margin inflammation, the secretory function of these glands is reduced and symptoms of dryness can greatly impact a patient's quality of life. The available literature indicates that isotretinoin's effect on the meibomian glands likely mimics its effects on the sebaceous glands of the skin in the treatment of acne. Several representative cases seen at the University of California Berkeley School of Optometry Dry Eye Clinic provide a clinical paradigm with the goal of raising awareness of the potential prevalence of this disease in patients who experience symptoms of dry eye. These cases highlight the importance of meibomian gland expression in determining whether there is poor quality and/or quantity of meibum secondary to reduced gland function. Currently, there is no definitive method to restore the structure and function of damaged meibomian glands; thus, treatment options for isotretinoin-associated meibomian gland dysfunction are primarily palliative to manage patient symptoms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26154692     DOI: 10.1097/OPX.0000000000000656

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  13 in total

1.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

Review 2.  Ocular surface inflammation impairs structure and function of meibomian gland.

Authors:  Shin Mizoguchi; Hiroki Iwanishi; Reiko Arita; Kumi Shirai; Takayoshi Sumioka; Masahide Kokado; James V Jester; Shizuya Saika
Journal:  Exp Eye Res       Date:  2017-10       Impact factor: 3.467

Review 3.  Proteolytic activity in the meibomian gland: Implications to health and disease.

Authors:  Pablo Argüeso
Journal:  Exp Eye Res       Date:  2017-03-08       Impact factor: 3.467

4.  Excessive serous retinal detachment during the use of isotretinoin.

Authors:  Mehmet Citirik; Kemal Tekin
Journal:  Int Ophthalmol       Date:  2017-02-25       Impact factor: 2.031

5.  Reduced ocular surface disease index (OSDI) scores in patients with isotretinoin treatment.

Authors:  Cagatay Caglar; Engin Senel; Emine Sabancilar; Mustafa Durmus
Journal:  Int Ophthalmol       Date:  2016-05-18       Impact factor: 2.031

6.  Presumed isotretinoin-induced extraocular myopathy.

Authors:  Md Shahid Alam; Swati Agarwal
Journal:  J Pharmacol Pharmacother       Date:  2016 Oct-Dec

7.  A clinical utility assessment of the automatic measurement method of the quality of Meibomian glands.

Authors:  Robert Koprowski; Lei Tian; Paweł Olczyk
Journal:  Biomed Eng Online       Date:  2017-06-24       Impact factor: 2.819

8.  Assessment of meibomian glands using a custom-made meibographer in dry eye patients in Ghana.

Authors:  Eugene Appenteng Osae; Reynolds Kwame Ablorddepey; Jens Horstmann; David Ben Kumah; Philipp Steven
Journal:  BMC Ophthalmol       Date:  2018-08-16       Impact factor: 2.209

9.  Histopathology and selective biomarker expression in human meibomian glands.

Authors:  Lixing W Reneker; Rebecca T Irlmeier; Ying-Bo Shui; Ying Liu; Andrew J W Huang
Journal:  Br J Ophthalmol       Date:  2019-10-04       Impact factor: 4.638

10.  An Eyelid Warming Device for the Management of Meibomian Gland Dysfunction.

Authors:  William Ngo; Sruthi Srinivasan; Lyndon Jones
Journal:  J Optom       Date:  2018-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.